South & Central America Organoids Services Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The South & Central America organoids services market size is expected to reach US$ 806.23 million by 2031 from US$ 194.86 million in 2024. The market is estimated to record a CAGR of 22.5% from 2024 to 2031.

Executive Summary and South & Central America Organoids Services Market Analysis:

The South & Central America organoids services market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the increasing number of cancer cases, growing government initiatives, and rising research and development for organoids. 

South & Central America Organoids Services Market Strategic Insights

Get more information on this report Request Free Sample PDF

South & Central America Organoids Services Market Segmentation Analysis

Key segments that contributed to the derivation of the South & Central America organoids services market analysis are type, application, and source

• By type, the South & Central America organoids services market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the market in 2024.
• By application, the South & Central America organoids services market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2024.
• By source, the South & Central America organoids services market is bifurcated into pluripotent stem cells and organ specific adult stem cell. The pluripotent stem cells segment held a larger share of the market in 2024.

South & Central America Organoids Services Market Outlook

The progress of the healthcare sector has led to a rise in the demand for organoids across the world. This increased demand contributes to new product developments, acquisitions, partnerships, product launches, and approvals on a global level. Major market players are involved in activities to ensure the innovation and development of efficient services and products. A few of the recent key developments are listed below:
In June 2024, Molecular Devices, LLC. formally opened its purpose-built facility in Cardiff, UK. The multimillion-pound facility was designed to accommodate the exclusive bioprocess workflow and innovative bioreactor technology of the business, allowing for the large-scale, quality-controlled production of PDOs. Substantial amounts of repeatable PDOs that are 3D-ready are available as a custom service and are cryopreserved in a manner that is ready for analysis. Researchers can defrost, plate, and use these products as needed.
In May 2024, InSphero, a biotech company, signed a partnership agreement with Genome Biologics, Frankfurt. In this partnership, InSphero will receive the exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform. The platform provides accurate, scalable, and disease-specific organoid models for creating novel treatments, placing it at the forefront of heart disease research. 
In January 2024, HUB Organoids (HUB) launched IntegriGut Screen services for the global market. This screening service employs IBD patient-derived organoid monolayers—PDO Monolayers—to aid in the availability of high-quality human data on epithelial barrier function, in turn accelerating the development of novel IBD therapies. 
In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications. In February 2023, Molecular Devices, LLC., and HUB Organoids (HUB) announced a strategic collaboration to contribute to the continued development of next-generation 3D biology technologies that enable step-change reduction in preclinical to clinical drug attrition. 
In December 2022, Molecular Devices, LLC. acquired Cellesce Ltd. This acquisition focuses on producing large-scale PDOs for various purposes, including drug screening, through contract development and production services. 
In August 2021, STEMCELL Technologies and Hubrecht Organoid Technology (HUB) signed an agreement. As a part of this agreement, STEMCELL's Contract Assay Services division began providing its tissue-derived organoids, such as lung, intestinal, liver organoids, for pre-clinical toxicology screening and non-cancer drug development services to HUB. These services would facilitate the integration of organoids into preclinical testing programs by researchers and drug development organizations to aid in the faster and more economical launch of new therapies. 
In May 2020, CELLINK collaborated with AstraZeneca to provide advanced 3D bioprinted liver organoids for drug discovery purposes in metabolic diseases, renal, and cardiovascular diseases. This collaboration allowed AstraZeneca to use Extra Cellular Matrix and Laminin-based bioinks from CELLINK. These are novel and patent-pending bioinks that allow human cells to proliferate and behave similarly to their behavior in the human body. 
In February 2020, InnoSer and Organotherapeutics announced a collaboration to provide midbrain organoids for drug discovery and screening. This collaboration was meant to make midbrain organoids commercially available as a platform for Parkinson's disease research.

Such key developments, launches, and strategic collaborations among market players create ample opportunities for the organoid services market growth.

South & Central America Organoids Services Market Country Insights

Based on country, the South & Central America organoids services market comprises Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest share in 2024.

The primary factor responsible for the organoid services market growth in Brazil is the increasing investment in biotechnology and life sciences, supported by government initiatives and private-sector funding to enhance research capabilities. Additionally, the rising prevalence of chronic diseases in the country underlines the urgent need for more effective drug development and personalized medicine solutions; organoids mimic human organ functions, thereby aiding in disease modeling and drug testing. The growing collaboration between academic institutions and industry players further accelerates the adoption of organoid technologies, facilitating the conversion of research into practical applications. Moreover, the focus on improving healthcare outcomes and the demand for more reliable preclinical models drive pharmaceutical companies to integrate organoids into their drug discovery processes, which benefits the organoid services market in Brazil.

South & Central America Organoids Services Market Report Highlights

South & Central America Organoids Services Market Company Profiles

Some of the key players operating in the market include CUSABIO TECHNOLOGY LLC; Cyprio; Eurofins Scientific SE; HUB Organoids B.V. (Hubrecht Organoid Technology); InnoSer; InSphero; LABTOO; Molecular Devices, LLC.; Oncodesign Services; and Sino Biological Inc., among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South & Central America Organoids Services Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

South & Central America Organoids Services Market Country and Regional Insights